)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bicara Therapeutics
Bicara Therapeutics (BCAX) investor relations material
Bicara Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary11 Aug, 2026
Executive summary
Multiple strategic leadership transitions announced, including new CEO, COO, CFO, and Chief Legal Officer, effective January 2027, to support commercialization and growth.
Focus remains on advancing FICERA (ficerafusp alfa), a bifunctional EGFR/TGF-β inhibitor, through pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer.
FICERA's pivotal trial showed nearly doubled three-year overall survival versus standard of care, with consistent safety profile.
Company is preparing for potential commercialization, expanding operational and commercial capabilities.
No commercial revenue to date; operations funded by equity offerings, including a $161.8M raise in February 2026.
Financial highlights
Q2 2026 operating expenses rose to $60.0M from $32.0M in Q2 2025, mainly due to higher R&D and personnel costs.
Research & development expenses were $45.8M in Q2 2026; G&A expenses increased to $14.2M.
Net loss for Q2 2026 was $55.4M, up from $27.4M in Q2 2025; six-month net loss was $111.6M.
Cash, cash equivalents, and marketable securities totaled $497.3M as of June 30, 2026.
Cash runway expected to fund operations into the first half of 2029.
Outlook and guidance
Substantial enrollment of pivotal FORTIFI-HN01 trial expected by year-end 2026, with interim topline results anticipated mid-2027.
FORTIFI-FLEX alternate dosing study initiated, with results expected in time for potential U.S. accelerated approval.
Strategic investments planned to maximize long-term value and support commercialization.
Data from Phase 1b expansion cohort in mCRC expected in the second half of 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bicara Therapeutics
- FICERA shows strong efficacy and durability in HPV-negative HNSCC, with pivotal trials underway.BCAX
Corporate presentation - Ficerafusp alfa plus pembrolizumab delivers high response and survival rates in HPV-negative head and neck cancer.BCAXStatus Update
- Lead bifunctional agent shows high efficacy and safety, with pivotal trial milestones set for 2026.BCAXPiper Sandler 37th Annual Healthcare Conference
- Ficera plus pembrolizumab doubled three-year survival and delivered deep, durable responses in HPV-negative HNSCC.BCAXStudy update
- Ficerafusp alfa delivers unprecedented durability in head and neck cancer, with pivotal data due mid-2025.BCAXBank of America Global Healthcare Conference 2026
- FICERA delivers deep, durable responses in HPV-negative HNSCC, supporting blockbuster potential.BCAXCorporate presentation
- Pivotal trial advanced, $161.8M raised, and cash runway extended into 2029.BCAXQ1 2026
- Proxy details director elections, auditor ratification, and governance for the 2026 annual meeting.BCAXProxy filing
- Advanced pivotal trial, secured breakthrough status, raised $161.8M, and reported $138M net loss.BCAXQ4 2025
Next Bicara Therapeutics earnings date
Q3 202610 Nov, 2026
Bicara Therapeutics
Next Bicara Therapeutics earnings date
Q3 202610 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bicara Therapeutics Inc. is a biopharmaceutical company focused on developing innovative immuno-oncology therapies for cancer treatment. The company specializes in creating biologics that combine tumor-targeting properties with immune modulation to improve treatment outcomes for patients with advanced or resistant cancers. Bicara’s research and development efforts are geared toward creating therapies that harness the body’s immune system to selectively target and combat cancer cells. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.